The clinical evidence for the use of low-dose naltrexone in mast cell activation syndrome remains limited but promising, consisting primarily of case reports and small case series rather than large randomised controlled trials. While LDN has not been specifically studied in rigorously controlled trials for MCAS, multiple clinical observations and mechanistic insights suggest it may be a valuable treatment option for this challenging condition.
Table of contents
- What is mast cell activation syndrome?
- Clinical evidence: case reports and case series
- Case report: MCAS + SIBO + hypermobility (Quinn, 2023) [1]
- Other published reports involving LDN in MCAS
- How might LDN work in MCAS? (proposed mechanisms)
- Relevance to mast cell pathophysiology
- Current therapeutic use and clinical dosing
- Limitations and knowledge gaps
- Future research directions
- References:
-
Ketotifen 1mg tabletsPrice range: £29.99 through £149.99 -
Ketotifen 1mg/5ml elixir (Zaditen) 300mlPrice range: £34.99 through £119.99
-
Nalcrom (sodium cromoglycate) 100mg capsulesPrice range: £99.99 through £399.99
What is mast cell activation syndrome?
Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells—immune cells that usually help protect you—become too easily triggered and release numerous chemicals (called “mediators”). This can cause allergy-like symptoms, but it often doesn’t fit a classic allergy pattern. The key problem is that symptoms can affect multiple organ systems simultaneously, fluctuate, and be challenging to identify.
This article will take a closer look at the evidence for using low-dose naltrexone for MCAS.
Clinical evidence: case reports and case series
The most direct clinical evidence comes from case reports documenting MCAS patients who responded to LDN therapy.
Case report: MCAS + SIBO + hypermobility (Quinn, 2023) [1]
In one notable case, a 42-year-old female patient with chronic small intestinal bacterial overgrowth (SIBO)-associated gastrointestinal complaints was diagnosed with MCAS and demonstrated immense improvement upon stabilisation with ketotifen, with remission of symptoms on low-dose naltrexone [1].
Case background
This case report describes a 42-year-old woman who initially presented to the clinic primarily for long-standing gastrointestinal symptoms, particularly small intestinal bacterial overgrowth (SIBO), with bloating and other digestive symptoms that hadn’t fully resolved. Over time, it became clear she also had symptoms in different areas, including anxiety, fatigue, fast heart rate (tachycardia), palpitations, flushing, muscle spasms, brain fog, and episodes of diarrhoea.
The “episodes” that raised suspicion for MCAS
A big clue was that she had repeated “episodes” that followed a similar pattern: she would feel hot/flushed or cold/clammy, get muscle spasms, notice a heart “thump” (like a skipped beat), and then have sudden diarrhoea. During these episodes, she also needed to urinate frequently. Notably, she found that an antihistamine (such as cetirizine or loratadine) could calm symptoms within 20–30 minutes. That kind of response raised suspicion for mast cell involvement.
The difficulty of diagnosing MCAS using mediators
Diagnosing MCAS can be tricky. Some diagnostic criteria rely on laboratory tests, such as serum tryptase rising during a flare, and on urine tests for other mediators. But many people with MCAS-like symptoms don’t get “positive” lab results at the right time. In this case, her baseline tryptase was normal, and she didn’t repeat it during a flare. Even so, the clinicians felt her multi-system symptoms, plus her clear response to antihistamines and mast cell stabilisers, made MCAS likely.
Common comorbid conditions associated with MCAS
They also noticed she had signs of joint hypermobility (Beighton score 7/9), which can link with conditions like hypermobile Ehlers-Danlos syndrome (hEDS). The paper highlights that MCAS often overlaps with other issues such as gut motility problems (including SIBO), dysautonomia/POTS, hypermobility disorders, and sometimes autoimmunity. The patient also reported chemical sensitivities, possible mould exposure, and a history of trauma/stress, all of which the authors discuss as possible contributors.
MCAS treatment protocol
Treatment was multi-layered. It included:
- H1 antihistamines (they preferred less-sedating options like fexofenadine)
- H2 blockers (like famotidine or cimetidine) instead of long-term proton pump inhibitors, due to safety concerns
- Ketotifen (a mast cell stabiliser), started at a very low dose because she was sensitive—this was a major turning point
- Quercetin and vitamin C (supportive, mast-cell-focused options)
- Low-dose naltrexone (LDN), used off-label; she gradually increased the dose and later had SIBO remission
- A histamine-friendly probiotic strain (Lactobacillus rhamnosus)
- Mind-body approaches like limbic retraining and neurofeedback, which she felt helped a lot
Patient outcome
The main outcome: once her mast cells were stabilised—especially with ketotifen—she felt better than she had in years, her episodes became much milder, and she could tolerate foods that used to trigger symptoms. The authors’ big takeaway is simple: when someone has unexplained symptoms across multiple systems, it’s worth considering MCAS and related overlap conditions, and that careful history-taking and clinical suspicion can change outcomes, even when lab tests aren’t clear.
In this case report, the most interesting “extra” piece is how low-dose naltrexone (LDN) was used alongside mast-cell treatment, and how it seemed to fit the patient’s overall picture [1].
Where LDN comes into the story
The patient’s primary reason for attending the clinic was chronic small intestinal bacterial overgrowth (SIBO) with ongoing gastrointestinal symptoms. She also had a long list of other issues—fatigue, anxiety, palpitations, flushing, brain fog, diarrhoea episodes—which later raised suspicion for MCAS.
After standard SIBO approaches (including antibiotics such as rifaximin) didn’t clearly resolve symptoms, the patient asked to try LDN. The clinicians agreed and started it very cautiously because she was sensitive to medications.
How they used LDN (and why)
LDN is naltrexone given at much lower doses than its usual use. In this paper, it’s described as an off-label option with no firm guidelines, often used in chronic inflammatory or immune-related conditions.
The authors give a few reasons LDN might help in a patient like this:
- Immune and inflammation signalling
- LDN may reduce inflammatory signalling partly by acting on Toll-like receptor 4 (TLR4).
- This matters because inflammatory pathways (like TNF-?, IL?1, interferons) may feed into immune overactivity, and the authors suggest these inflammatory proteins can be linked with mast cell activation.
- Effects in the nervous system (glial modulation)
- The paper highlights LDN as a “glial modulator, meaning it may calm certain inflammatory responses in the nervous system.
- That’s relevant because MCAS symptoms can include brain fog, headaches, anxiety-like symptoms, and other nervous-system-type complaints.
- Possible gut motility support
- The authors discuss a theory that LDN may support the migrating motor complex (MMC) and gut movement.
- That’s important because poor motility can contribute to SIBO, and improving motility is often part of preventing relapse.
What happened after LDN was started
- LDN was started at 0.5 mg nightly and slowly increased up to 4.5 mg nightly.
- The patient responded well to the gradual titration.
- The paper reports remission of SIBO with LDN, which is a big claim in the context of a single case (so: promising, but not proof).
How LDN fits with the MCAS treatment
Low-dose naltrexone wasn’t presented as the only answer. In fact, the case makes it clear that the patient’s most significant “turning point” in the whole multi-system flare pattern was mast cell stabilisation, especially ketotifen (even at a small dose).
So the way to read this case is:
- LDN seemed to play a key role in SIBO remission/relapse prevention, possibly via immune modulation and/or motility effects.
- Ketotifen + antihistamine strategy seemed to be the key for the MCAS-style episodes (flushing/clamminess, palpitations, diarrhoea flares, etc.).
- Together, they helped the patient move from “constant chaos” to “stable enough to expand diet and function usually.
The honest limitation (but still useful)
The authors are upfront that evidence for LDN in MCAS (and even in SIBO) is still mostly case reports and small studies, not big randomised trials. But this case is useful because it shows:
- how clinicians dose it carefully in sensitive patients,
- how it’s used as part of a layered plan, and
- What kind of outcomes are possible when the MCAS + gut dysmotility overlap is treated as one connected problem?
Other published reports involving LDN in MCAS
MCAS with erythromelalgia (Kurta et al., 2020) [2]
Another case report described a patient with MCAS who developed erythromelalgia, a rare painful condition characterised by episodic burning, erythema, and swelling, and this patient responded well to low-dose naltrexone treatment [2].
POTS + MCAS treated with a combined approach (Weinstock et al., 2018) [3]
In a particularly informative case series, a patient with severe postural orthostatic tachycardia syndrome (POTS) and MCAS received low-dose naltrexone in addition to intravenous immunoglobulin and antibiotic therapy for small intestinal bacterial overgrowth [3]. This patient demonstrated a dramatic and sustained response to the combined treatment regimen.
Neuropsychiatric symptoms in MCAS (Weinstock et al., 2023) [4]
More recently, a larger case series examining neuropsychiatric manifestations of MCAS reported that patients with various neuropsychiatric disorders associated with MCAS, including headaches, dysautonomia, depression, generalised anxiety disorder, and panic disorder, experienced improvements in their symptoms following mast-cell-directed therapy [4]. Six of these patients had comorbid autonomic disorders, with postural orthostatic tachycardia syndrome and hypermobile Ehlers-Danlos syndrome being the most common.
How might LDN work in MCAS? (proposed mechanisms)
Understanding how LDN might benefit MCAS patients requires consideration of its complex pharmacological properties. At doses of 3-5 mg daily, low-dose naltrexone operates through mechanisms quite distinct from its use at higher doses for opioid antagonism.
1) Endorphin and immune modulation [5]
As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphin levels by transiently blocking opioid receptors, which then bind to regulatory T cells that regulate T-lymphocyte and B-lymphocyte production and reduce cytokine and antibody production [5]. This endogenous opioid upregulation represents a key mechanism through which LDN may modulate immune responses.
2) TLR4 and inflammatory signalling [5–6]
Beyond opioid receptor antagonism, LDN has been shown to reduce the glial inflammatory response by modulating Toll-like receptor 4 (TLR4) signalling and to systemically upregulate endogenous opioid signalling through transient opioid receptor blockade [5].
The TLR4 pathway is particularly relevant to MCAS pathophysiology, as toll-like receptors play significant roles in innate immune responses and mast cell activation. LDN can blunt innate immune responses and TLR signalling, reducing interleukin-1, tumour necrosis factor-alpha, and interferon levels [6]. These anti-inflammatory effects are mediated by modulation of microglial activation in the central nervous system, a mechanism demonstrated in multiple cellular studies.
3) Microglial (brain immune cell) effects [5–7]
In vitro studies have provided insights into LDN’s immunomodulatory effects on microglial cells [7]. Low-dose naltrexone induced a shift from a highly activated pro-inflammatory phenotype (characterised by high inducible nitric oxide synthase and low CD206 expression) to a quiescent anti-inflammatory M2-like phenotype (with low inducible nitric oxide synthase and high CD206 expression) in BV-2 microglia cells [7].
These changes in the inflammatory profile were accompanied by cellular metabolic switching based on the transition from high glycolysis to mitochondrial oxidative phosphorylation. The metabolic shift induced by the transition from glycolysis to mitochondrial oxidative metabolism was more prominent in cells pretreated with immunometabolic modulators such as lipopolysaccharide and interferon-gamma.
Notably, naltrexone also modulated mechanistic target of rapamycin (mTOR) and S6K expression in a dose-dependent manner, which underlies the cellular metabolic phenotype that regulates microglial immune properties and adaptation.
Relevance to mast cell pathophysiology
The mechanisms by which low-dose naltrexone might benefit MCAS patients are particularly intriguing when considered in the context of mast cell biology and the role of toll-like receptors.
Research has demonstrated that various stimuli can activate toll-like receptors on mast cells, and activation of these receptors can modulate mast cell responses [8].
Moreover, emerging evidence indicates that mast cell-derived tumour necrosis factor plays important roles in immunomediated chronic illness and autoimmunity, and that treatments such as low-dose naltrexone may interact with mast cell dysfunction through multiple pathways [9].
The hypothesis has been proposed that there is interplay among mast cell-derived TNF, mitochondrial dysfunction, microglial activation, and the hypothalamic-pituitary-adrenal axis, all of which are pathways of action for treatments such as high-dose melatonin and low-dose naltrexone.
Current therapeutic use and clinical dosing
In clinical practice for mast cell activation syndrome or MCAS, LDN is used as an off-label treatment, typically at doses of 3-4.5 mg once daily. The therapeutic response appears to be variable among patients, and the effective dose may be idiosyncratic, suggesting the need for individualised dosage titration [10].
Some clinical experience suggests that low-dose naltrexone may be particularly useful as an adjunctive therapy alongside other mast cell-stabilising agents and antihistamines rather than as a monotherapy.
Limitations and knowledge gaps
Despite the encouraging clinical observations, significant limitations exist in the current evidence base. There are no large-scale randomised controlled trials specifically investigating LDN in MCAS populations, and all published evidence consists of case reports and small case series.
The patient populations in published reports are heterogeneous, with MCAS often co-existing with other conditions such as postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and dysautonomia, making it difficult to attribute therapeutic benefits specifically to the treatment of MCAS itself.
Additionally, the long-term safety profile and optimal dosing regimens for LDN in patients with MCAS remain undefined. The mechanisms by which low-dose naltrexone might benefit MCAS specifically, as opposed to other immune-mediated conditions, require further investigation.
Future research directions
Future investigation should focus on designing prospective, controlled clinical trials specifically evaluating low-dose naltrexone in well-characterised MCAS populations with appropriate diagnostic testing, including tryptase levels and other relevant biomarkers.
Such studies should evaluate objective measures of mast cell activation and patients’ symptom burden. Research should also explore potential biomarkers that predict which MCAS patients are most likely to respond to LDN therapy, and investigate optimal dosing strategies and potential drug interactions with other commonly used MCAS treatments.
In conclusion, while the evidence for low-dose naltrexone in MCAS remains preliminary, consisting mainly of encouraging case reports, the proposed mechanisms of action involving immune modulation, microglial regulation, and toll-like receptor antagonism are theoretically sound and warrant further investigation through rigorous clinical trials.
References:
Are weight loss treatments making you tired, or have they led to a sudden increase in hair loss? Do you struggle with sleep?
Get a free month’s supply of one of our compounded treatments for energy, hair loss or sleep, with your first purchase of Mounjaro or Wegovy from Medical Mojo.
Claim your FREE offer
